Toward patient-friendly cell-level dosimetry.

Dosimetry for targeted radionuclide therapy is a relatively young field. Although initial work can be traced back to the late 1940s (1), the MIRD Committee formalism that forms the foundation for most current approaches was published in the mid 1970s (2), and the drive for improved dosimetry to meet the requirements of targeted radionuclide therapy did not begin until the 1980s. During this period, the absorbed fraction and S value tables of MIRD Pamphlet 11 (3) and subsequently the values published by Cristy, Eckerman, and Stabin (4,5) and implemented in the software package MIRDOSE3 (6) formed the basis for almost all dosimetry calculations.